<DOC>
	<DOCNO>NCT01420861</DOCNO>
	<brief_summary>The purpose study assess effect GTx-758 Serum Prostate-specific antigen ( PSA ) level men castrate resistant prostate cancer maintain androgen deprivation therapy ( Serum PSA response Serum PSA progression )</brief_summary>
	<brief_title>GTx-758 Serum Prostate-specific Antigen ( PSA ) Men With Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Be 18 year age 2 . Be able communicate effectively study personnel 3 . Have histologically confirm prostate cancer 4 . ECOG performance status 0 2 5 . Have treat ADT ( chemical surgical ) least 6 month 6 . Have castrate level serum total testosterone ( &lt; 50 ng/dL ) 7 . Have history serum PSA response initiation ADT , serum PSA response least 90 % reduction serum PSA &lt; 10 ng/mL OR undetectable level serum PSA ( less tan =0.2 ng/mL ) 8 . Have rise serum PSA two successive assessment least 2 week apart serum PSA level â‰¥ 2 ng/mL 2ng/mL 25 % increase nadir initiation ADT 9 . Be continue androgen deprivation therapy throughout study 10 . Give write informed consent prior study specific procedures 11 . Subjects must agree use acceptable method contraception : oIf female partner pregnant lactate acceptable method contraception time first administration study medication 3 month follow administration last dose study medication must use . Acceptable method : Condom use spermicidal foam/gel/film/cream/suppository . If subject undergone surgical sterilization ( vasectomy documentation azospermia ) condom spermicidal foam/gel/film/cream/suppository use . oIf male subject 's partner could become pregnant , use acceptable method contraception time first administration study medication 3 month follow administration last dose study medication . Acceptable method contraception follow : Condom spermicidal foam/gel/film/cream/suppository [ i.e . barrier method contraception ] , surgical sterilization ( vasectomy documentation azospermia ) barrier method { condom use spermicidal foam/gel/film/cream/suppository } , female partner use oral contraceptive ( combination estrogen/progesterone pills ) , injectable progesterone subdermal implant barrier method { condom use spermicidal foam/gel/film/cream/suppository } . oIf female partner undergone document tubal ligation ( female sterilization ) , barrier method { condom use spermicidal foam/gel/film/cream/suppository } also use . oIf female partner undergone document placement intrauterine device ( IUD ) intrauterine system ( IUS ) barrier method { condom spermicidal foam/gel/film/cream/suppository } also use . 1 . Known hypersensitivity allergy estrogen estrogen like drug ; 2 . Have symptomatic metastatic prostate cancer 3 . Any disease condition ( medical surgical ) might compromise hematologic , cardiovascular , endocrine , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition may interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk ; 4 . History abnormal blood clotting , Factor V Leiden clot disorder , thrombotic disease ( venous arterial thrombotic event history stroke , deep vein thrombosis ( DVT ) , and/or pulmonary embolus ( PE ) ) 5 . Symptomatic congestive heart failure ( NYHA Class III IV ) , unstable angina pectoris , cardiac arrhythmia 6 . The presence consistently abnormal laboratory value consider clinically significant . In addition , subject liver enzyme ( ALT AST ) 2 time ULN , total bilirubin 2 time ULN , serum creatinine 1.5 ULN admit study 7 . Received investigational drug within period 90 day prior enrollment study 8 . Received study medication previously 9 . Currently take testosterone , testosteronelike agent , antiandrogens , include 5alpha reductase inhibitor ( may eligible allow 6 week washout period stop antiandrogens ) ; 10 . History prior treatment cancer chemotherapy agent ( hormone therapy ) radiopharmaceutical prostate cancer . 11 . Have take ketoconazole within previous 12 month prior randomization study 12 . Have take diethylstilbestrol estrogen product , ketoconazole , abiraterone within previous 12 month prior randomization study 13 . Have take body build fertility supplement within 4 week admission study 14 . Have previously diagnose cancer ( prostate cancer , superficial bladder cancer , nonmelanoma skin cancer ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>castrate resistant</keyword>
</DOC>